Follow-up and Extended Follow-up of Participants - Option 1

Fundacion Inciensa, San Jose

Investigators

Abstract

This SOW describes activities related to NCI’s Human Papillomavirus (HPV) vaccine evaluation efforts required for the next phase of these studies and will cover the follow-up of participants in both the existing trial of the bivalent HPV vaccine (Costa Rica Vaccine Trial or CVT) and the new trial aimed at evaluating the non-inferiority of 1 versus 2 doses of the HPV vaccines. Human papillomavirus (HPV) vaccination successfully prevents targeted HPV infections, related precancerous lesions, and ultimately has the potential to substantially reduce cervical and other HPV-related cancers. Despite the established efficacy and safety of the HPV vaccine, most girls living in areas with the greatest risk for cervical cancer are not being vaccinated. The cost and logistical difficulties of the recommended multiple-dose schedule has been a significant impediment to vaccination uptake and the prevention of cervical cancer and its associated mortality. Task A and Task B will run concurrently.